OBI vs. FARN, VRP, ARIX, 4BB, AVCT, CIR, BVXP, TILS, VSN, and HVO
Should you be buying Ondine Biomedical stock or one of its competitors? The main competitors of Ondine Biomedical include Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), 4basebio (4BB), Avacta Group (AVCT), Circassia Group (CIR), Bioventix (BVXP), Tiziana Life Sciences (TILS), Verseon (VSN), and hVIVO (HVO). These companies are all part of the "biotechnology" industry.
Ondine Biomedical vs.
Faron Pharmaceuticals Oy (LON:FARN) and Ondine Biomedical (LON:OBI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.
10.7% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 20.6% of Ondine Biomedical shares are owned by institutional investors. 31.8% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 36.7% of Ondine Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Faron Pharmaceuticals Oy has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, Ondine Biomedical has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.
In the previous week, Ondine Biomedical had 2 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 3 mentions for Ondine Biomedical and 1 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.75 beat Ondine Biomedical's score of 0.14 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.
Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Ondine Biomedical's net margin of -873.84%. Faron Pharmaceuticals Oy's return on equity of 0.46% beat Ondine Biomedical's return on equity.
Ondine Biomedical has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.
Faron Pharmaceuticals Oy received 316 more outperform votes than Ondine Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ondine Biomedical an outperform vote while only 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote.
Summary
Ondine Biomedical beats Faron Pharmaceuticals Oy on 8 of the 14 factors compared between the two stocks.
Get Ondine Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ondine Biomedical Competitors List
Related Companies and Tools
This page (LON:OBI) was last updated on 4/2/2025 by MarketBeat.com Staff
Buy OBI Stock Free OBI Stock Alerts